Publications by authors named "Bartosz Chmielowski"

97Publications

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).

J Clin Oncol 2018 04 12;36(12):1232-1239. Epub 2018 Mar 12.

Richard D. Carvajal and Gary K. Schwartz, Columbia University Medical Center; Paul B. Chapman and Alexander N. Shoushtari, Memorial Sloan Kettering Cancer Center, New York, NY; Sophie Piperno-Neumann and Manuel J. Rodrigues, Institut Curie, Paris; Lauris Gastaud, Centre Antoine-Lacassagne, Nice, France; Ellen Kapiteijn, Leiden University Medical Center, Leiden, the Netherlands; Stephen Frank, Hebrew University Hadassah Medical School - The Sharett Institute of Oncology, Jerusalem; Jacob Schachter, Sheba Medical Center at Tel Hashomer, and Tel-Aviv University Medical School, Tel Aviv, Israel; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Josep M. Piulats, Institut Catala d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Pascal Wolter, University Hospitals Leuven, Leuven, Belgium; Veronique Cocquyt, Ghent University Hospital, Ghent, Belgium; Bartosz Chmielowski, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; T.R. Jeffry Evans, University of Glasgow, Glasgow; Delyth Clemett, Shirley Spratt, Susan Lovick, and Elaine Kilgour, AstraZeneca, Macclesfield; Dana Ghiorghiu and Gabriella Mariani, AstraZeneca, Cambridge; Paul Nathan, Mt Vernon Cancer Centre, Northwood, United Kingdom; Gerald Linette, Washington University School of Medicine, St Louis, MO; Carola Berking, University Hospital of Munich, Munich, Germany; Peter Barker, AstraZeneca, Gaithersburg, MD; and Zhongwu Lai, AstraZeneca, Waltham, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.1090DOI Listing
April 2018

How Should We Assess Benefit in Patients Receiving Checkpoint Inhibitor Therapy?

J Clin Oncol 2018 03 1;36(9):835-836. Epub 2018 Feb 1.

Bartosz Chmielowski, University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.9885DOI Listing
March 2018

Endocrinopathies with use of cancer immunotherapies.

Clin Endocrinol (Oxf) 2018 02 9;88(2):327-332. Epub 2017 Oct 9.

Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cen.13483DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771947PMC
February 2018

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

J Clin Oncol 2018 02 3;36(4):383-390. Epub 2017 Jul 3.

James Larkin, Royal Marsden NHS Foundation Trust, London; Paul Lorigan, The Christie National Health Service Foundation Trust, Manchester, United Kingdom; David Minor, California Pacific Medical Center Research Institute; Adil Daud, University of California San Francisco, San Francisco; Bartosz Chmielowski, University of California, Santa Monica, CA; Sandra D'Angelo, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College; Jeffrey Weber, Perlmutter Cancer Center at New York University-Langone Medical Center, New York; Nikhil Khushalani, Roswell Park Cancer Institute, Buffalo, NY; Gerald Linette, Washington University, St. Louis, MO; Christopher D. Lao, University of Michigan, Ann Arbor, MI; Kenneth Grossmann, Huntsman Cancer Institute, Salt Lake City, UT; Mario Sznol, Yale Comprehensive Cancer Center, New Haven, CT; Jeffrey Sosman, Northwestern University, Chicago, IL; Dana Walker, George Kong, and Christine Horak, Bristol-Myers Squibb, Princeton, NJ; Bart Neyns, University Hospital, Vrije Universiteit Brussel, Brussels, Belgium; Michael Smylie, Cross Cancer Institute, Edmonton, Alberta; Wilson H. Miller Jr, Jewish General Hospital and Segal Cancer Centre, McGill University, Montreal, Quebc, Canada; Ralf Gutzmer, Medizinische Hochschule Hannover, Hannover; Jessica C. Hassel, Nationale Centrum für Tumorerkrankungen Heidelberg, Heidelberg; Dirk Schadendorf, University Hospital Essen, Essen, Germany; and Christoph Hoeller, Medical University of Vienna, Wien, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.8023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804912PMC
February 2018

Is there a role for single-agent BRAF inhibition in melanoma?

Clin Adv Hematol Oncol 2017 Feb;15(2):108-110

UCLA Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California.

View Article

Download full-text PDF

Source
February 2017

Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States.

J Manag Care Spec Pharm 2017 Feb;23(2):184-194

2 Outcomes Research - Oncology, Center for Observational and Real World Evidence (CORE), Merck Research Laboratories, Merck & Co, North Wales, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18553/jmcp.2017.23.2.184DOI Listing
February 2017

Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma.

Cancer Immunol Res 2017 02 30;5(2):118-126. Epub 2016 Dec 30.

Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-16-0148DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290092PMC
February 2017

Clinical Factors That Affect the Establishment of Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts: A University of California, Los Angeles, Sarcoma Program Prospective Clinical Trial.

JCO Precis Oncol 2017 4;2017. Epub 2017 Aug 4.

Tara A. Russell, Irmina A. Elliott, Yungfeng Li, Joseph G. Crompton, Danielle S. Graham, Sarah M. Dry, Nicholas Bernthal, Jane Yanagawa, Anusha Kalbasi, Noah Federman, Bartosz Chmielowski, Arun S. Singh, and Fritz C. Eilber, University of California, Los Angeles; Tara A. Russell, Veterans Affairs Los Angeles Health Services Research & Development Center of Innovation, Los Angeles, CA; Mark A. Eckardt, Yale School of Medicine, New Haven, CT; Takashi Murakami, Kei Kawaguchi, Tasuku Kiyuna, Kentaro Igarashi, and Robert M. Hoffman, AntiCancer; and Takashi Murakami, Kei Kawaguchi, Tasuku Kiyuna, Kentaro Igarashi, and Robert M. Hoffman, University of California, San Diego, San Diego, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.17.00071DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319895PMC
August 2017

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

N Engl J Med 2016 Sep 13;375(9):819-29. Epub 2016 Jul 13.

From the University of California, Los Angeles (UCLA) (J.M.Z., A.G.-D., D.S.S., H.E.-O., W.H., S.H.-L., D.Y.T., G.A.-R., S.S., L.B., J.S., B.H.M., B.C., K.R., I.P.S., P.J.S., C.P.-S., G.C., E.S., X.K., J.P., B.B.-M., B.C.-A., T.G.G., P.C.T., R.S.L., A.R.), and Jonsson Comprehensive Cancer Center (B.C., B.C.-A., T.G.G., P.C.T., R.S.L., A.R.) - both in Los Angeles; and the Division of Immunology, Netherlands Cancer Institute, Amsterdam (R.M., T.N.M.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1604958DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007206PMC
September 2016

CRAF R391W is a melanoma driver oncogene.

Sci Rep 2016 06 8;6:27454. Epub 2016 Jun 8.

Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep27454DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4897636PMC
June 2016

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Cell 2016 Mar 17;165(1):35-44. Epub 2016 Mar 17.

Division of Dermatology, Department of Medicine, University of California, Los Angeles, CA 90095-1662, USA; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095-1662, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095-1662, USA; David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1662, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2016.02.065DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808437PMC
March 2016

PD-1 Blockade Expands Intratumoral Memory T Cells.

Cancer Immunol Res 2016 Mar 19;4(3):194-203. Epub 2016 Jan 19.

Division of Surgical-Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, California. Jonsson Comprehensive Cancer Center, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0210DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775381PMC
March 2016

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.

Eur J Cancer 2015 Nov 10;51(17):2689-97. Epub 2015 Sep 10.

Department of Medicine, Division of Hematology/Oncology, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.08.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821004PMC
November 2015

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

N Engl J Med 2015 Jul;373(5):428-37

From Memorial Sloan Kettering Cancer Center (W.D.T., J.H.H.) and Weill Cornell Medical College (W.D.T.) - both in New York; University of California, Los Angeles, Medical Center, Los Angeles (Z.A.W., B.C., A.S.S.), Plexxikon, Berkeley (P.N.I., C.Z., J.Z., G.H., Y.Z., E.A.B., G.V., L.S., P.S., H.N., M.J.K., A.M., G.T., R.S., C.G., B.L.W., P.H., K.N., H.H.H., P.S.L., S.T.-S., G.B.), and Stanford University School of Medicine, Stanford (M.R.) - all in California; Evergreen Hematology and Oncology, Spokane, WA (S.P.A.); University of Pennsylvania School of Medicine, Philadelphia (A.P.S.); Rocky Mountain Cancer Centers, Denver (A.L.C.); Dana-Farber Cancer Institute (G.I.S., A.J.W.) and Massachusetts General Hospital (E.L.K.) - both in Boston; Vanderbilt University Medical Center, Nashville (V.L.K., I.P.); Virginia G. Piper Cancer Center at Scottsdale Healthcare-Translational Genomics Research Institute (TGen), Scottsdale, AZ (D.D.V.H., G.J.W., R.K.R.); and Spire Sciences, Boca Raton, FL (C.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1411366DOI Listing
July 2015

Risk stratification of patients undergoing pulmonary metastasectomy for soft tissue and bone sarcomas.

J Thorac Cardiovasc Surg 2015 Jan 18;149(1):85-92. Epub 2014 Sep 18.

Division of Thoracic Surgery, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, Calif. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtcvs.2014.09.039DOI Listing
January 2015

Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA.

Proc Natl Acad Sci U S A 2014 Aug 21;111(31):11449-54. Epub 2014 Jul 21.

College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan;Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010;

View Article

Download full-text PDF

Source
http://www.pnas.org/cgi/doi/10.1073/pnas.1411393111
Publisher Site
http://dx.doi.org/10.1073/pnas.1411393111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128111PMC
August 2014

Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer.

JAMA Ophthalmol 2014 Aug;132(8):1005-9

Department of Ophthalmology and Jules Stein Eye Institute, Ophthalmic Oncology Center, University of California, Los Angeles.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaophthalmol.2014.976DOI Listing
August 2014

Insulin-like growth factor 1 receptor inhibitors: where do we come from? What are we? Where are we going?

Cancer 2014 Aug 2;120(16):2384-7. Epub 2014 May 2.

Division of Hematology-Medical Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.28727
Publisher Site
http://dx.doi.org/10.1002/cncr.28727DOI Listing
August 2014

Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.

Clin Cancer Res 2014 May 14;20(9):2457-65. Epub 2014 Mar 14.

Authors' Affiliations: Departments of Medicine, Surgery, Pathology and Laboratory Medicine, Microbiology, Immunology and Molecular Genetics, and Molecular and Medical Pharmacology; Jonsson Comprehensive Cancer Center; Department of Ophthalmology, Jules Stein Eye Institute; Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research; Howard Hughes Medical Institute, University of California, Los Angeles (UCLA); The Angeles Clinic Research Institute, Los Angeles; Department of Medicine, University of California San Diego (UCSD) Moores Cancer Center, La Jolla; Divisions of Chemistry and Biology, California Institute of Technology, Pasadena, California; Department of Medical and Molecular Genetics, Indiana University, and the Indiana University Viral Production Facility (IU VPF), Indianapolis, Indiana; Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada; Mayo Clinic Scottsdale, Scottsdale, Arizona; Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut; and Center for Immunology, Roswell Park Cancer Institute, Buffalo, New York.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-3017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070853PMC
May 2014

The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics.

J Clin Pharmacol 2014 Apr 22;54(4):368-74. Epub 2014 Jan 22.

Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.255DOI Listing
April 2014

Safety and efficacy of stereotactic body radiation therapy in the treatment of pulmonary metastases from high grade sarcoma.

Sarcoma 2013 1;2013:360214. Epub 2013 Oct 1.

Department of Radiation Oncology, David Geffen School of Medicine at UCLA, 200 UCLA Medical Plaza, B265, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2013/360214DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807836PMC
November 2013

Natural killer T cells in advanced melanoma patients treated with tremelimumab.

PLoS One 2013 22;8(10):e76829. Epub 2013 Oct 22.

Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America ; UCLA AIDS Institute, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0076829PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805549PMC
May 2014

Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma.

J Skin Cancer 2013 21;2013:423829. Epub 2013 Apr 21.

Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2013/423829DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665248PMC
June 2013

Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma.

J Clin Oncol 2013 Apr 18;31(12):e215-7. Epub 2013 Mar 18.

Westmead Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.45.7028DOI Listing
April 2013

Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas.

Expert Rev Anticancer Ther 2012 Sep;12(9):1217-28

Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, University of California Los Angeles, Santa Monica, CA 90404, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.12.100DOI Listing
September 2012

Do we need a different set of response assessment criteria for tumor immunotherapy?

Clin Cancer Res 2009 Dec 24;15(23):7116-8. Epub 2009 Nov 24.

Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, Los Angeles, California 90095-1782, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-2376DOI Listing
December 2009

The specific T-cell response to antigenic peptides is influenced by bystander peptides.

Cell Mol Biol Lett 2006 ;11(1):70-9

Laboratory of Immunogenetics, Department of Clinical Immunology, Polish Academy of Sciences, Wrocław, Poland.

View Article

Download full-text PDF

Source
http://www.degruyter.com/view/j/cmble.2006.11.issue-1/s11658
Publisher Site
http://dx.doi.org/10.2478/s11658-006-0007-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275589PMC
July 2009

Presentation of antagonist peptides to naive CD4+ T cells abrogates spatial reorganization of class II MHC peptide complexes on the surface of dendritic cells.

Proc Natl Acad Sci U S A 2002 Nov 31;99(23):15012-7. Epub 2002 Oct 31.

Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta 30912, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.222463499DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC137536PMC
November 2002